Avicanna (TSE:AVCN)
TSX:AVCN
Want to see TSE:AVCN full AI Analyst Report?
AVCN Stock Chart & Stats
C$0.22
C$0.02(4.41%)
At close: 4:00 PM EST
C$0.22
C$0.02(4.41%)
Day’s Range― - ―
52-Week RangeC$0.14 - C$0.31
Previous CloseN/A
Volume8.50K
Average Volume (3M)55.79K
Market Cap
C$18.87M
Enterprise ValueC$17.96M
Total Cash (Recent Filing)C$280.63K
Total Debt (Recent Filing)C$0.00
Price to Earnings (P/E)―
Beta1.27
Next Earnings
May 18, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding125,791,870
10 Day Avg. Volume77,161
30 Day Avg. Volume55,794
Financial Highlights & Ratios
PEG Ratio0.29
Price to Book (P/B)9.08
Price to Sales (P/S)1.01
P/FCF Ratio-17.96
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
High Gross MarginA 53% gross margin on the current revenue base indicates strong unit economics and pricing power for Avicanna’s cannabinoid formulations. Sustained high gross margins provide structural capacity to absorb SG&A, support capital-light scaling, and improve the path to consistent profitability if sales stabilize or grow.
Low Leverage / De-risked Balance SheetNear-zero debt and restored positive equity materially reduce insolvency and interest-rate risk, giving management flexibility to execute product rollouts and clinical programs without heavy interest burdens. This structural de-risking improves resilience through regulatory or revenue volatility.
Proprietary Delivery Platforms & Clinical ProgressProprietary SEDD platforms and positive bioavailability data create durable product differentiation and defendable IP. Combined with RWE publication and active Phase I/II work, this entrenches an innovation-led pipeline that can open pharmaceutical channels and sustain higher-margin specialty product revenue long-term.
Bears Say
Negative Cash FlowPersistent negative operating and free cash flow means the business is not yet self-funding and remains dependent on external capital or further cost cuts. Over months, this constrains reinvestment in commercialization and R&D and increases dilution or execution risk if margins or sales deteriorate.
Stalled Top-line GrowthFlat-to-declining revenue despite improved margins limits operating leverage and delays conversion of gross-profit strength into sustainable net profits. Reliance on a single core market and early-stage international sales mean scaling is uncertain and revenue volatility can erase margin gains.
Execution & Regulatory RiskSignificant upside relies on regulatory outcomes (U.S. rescheduling, approvals) and nascent product launches. Early-stage commercialization (soft launches) plus product pruning and outsourced manufacturing raise execution risk, which can delay revenue realization and stress margins across quarters.
Avicanna News
AVCN FAQ
What was Avicanna’s price range in the past 12 months?
Avicanna lowest stock price was C$0.14 and its highest was C$0.31 in the past 12 months.
What is Avicanna’s market cap?
Avicanna’s market cap is C$18.87M.
When is Avicanna’s upcoming earnings report date?
Avicanna’s upcoming earnings report date is May 18, 2026 which is in 20 days.
How were Avicanna’s earnings last quarter?
Avicanna released its earnings results on Apr 01, 2026. The company reported -C$0.008 earnings per share for the quarter, missing the consensus estimate of N/A by -C$0.008.
Is Avicanna overvalued?
According to Wall Street analysts Avicanna’s price is currently Overvalued.
Does Avicanna pay dividends?
Avicanna does not currently pay dividends.
What is Avicanna’s EPS estimate?
Avicanna’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Avicanna have?
Avicanna has 125,791,870 shares outstanding.
What happened to Avicanna’s price movement after its last earnings report?
Avicanna reported an EPS of -C$0.008 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Avicanna?
Currently, no hedge funds are holding shares in TSE:AVCN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Avicanna
Avicanna Inc., a commercial-stage biopharmaceutical company, engages in the research and development of evidence-based products for consumer medical and pharmaceutical segments worldwide. The company collaborates with Canadian academic and medical institutions. Its scientific platform includes research and development, and clinical development that leads to the commercialization of approximately twenty products across four main market segments. The company provides medical and wellness products containing cannabidiol, cannabigerol, and tetrahydrocannabinol under the RHO Phyto brand; functional CBD consumer derma-cosmetic and topical products under the Pura H&W and Pura Earth brand names; and cannabis dried flowers, standardized seeds, full spectrum extracts, cannabinoid distillates, isolated cannabinoids, and bulk formulations derived from hemp and cannabis cultivars under the Aureus brand. It also develops pharmaceutical products for epidermolysis bullosa, dermatology, chronic pain, and various neurological disorders. The company has research collaboration with Dr. Christine Allen'sResearch Group for the development of a cannabinoid-based treatment for lung inflammation associated with COVID19. Avicanna Inc. was incorporated in 2016 and is headquartered in Toronto, Canada.
Technical Analysis
Charlotte's Web Holdings
―
MediPharm Labs
―
PharmaCielo
―
Cardiol Therapeutics
―
InnoCan Pharma
―
Options Prices
Currently, No data available
---